Article
Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.
The Journal of clinical investigation - 1 Aug 2008
Ghevaert Cedric, Wilcox David A, Fang Juan, Armour Kathryn L, Clark Mike R, Ouwehand Willem H, Williamson Lorna M
Abstract excerpt
Fetomaternal alloimmune thrombocytopenia (FMAIT) is caused by maternal generation of antibodies specific for paternal platelet antigens and can lead to fetal intracranial hemorrhage. A SNP in the gene encoding integrin beta3 causes a clinically important maternal-paternal antigenic difference; Leu33 generates the human platelet antigen 1a (HPA-1a), whereas Pro33 generates HPA-1b. As a potential treatment to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.